OmniAb Inc (OABI) FinancialsOABIOmniAb Inc

OmniAb Inc (OABI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is License and milestone revenue, accounting for 70.9% of total sales, equivalent to $9.52M. Other significant revenue streams include Service revenue and xPloration revenue. Understanding this composition is critical for investors evaluating how OABI navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, OmniAb Inc maintains a gross margin of 72.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -49.47%, while the net margin is -43.67%. These profitability ratios, combined with a Return on Equity (ROE) of -16.95%, provide a clear picture of how effectively OABI converts its operational activities into shareholder value.

In the context of the broader market, OABI competes directly with industry leaders such as RSVR and TECX. With a market capitalization of $491.42M, it holds a significant position in the sector. When comparing efficiency, OABI's gross margin of 72.69% stands against RSVR's 44.35% and TECX's N/A. Such benchmarking helps identify whether OmniAb Inc is trading at a premium or discount relative to its financial performance.

OmniAb has shown a strong revenue trajectory, with Q2 2026 revenue of $13.4 million, a 244% increase year-over-year. The gross margin improved to 72.69% in Q2 2026, up from 58.11% in Q1 2026, indicating better cost management and profitability potential.